| Gaucher Disease, Type 1
Cerdelga vs Elelyso
Side-by-side clinical, coverage, and cost comparison for gaucher disease, type 1.Deep comparison between: Cerdelga vs Elelyso with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsElelyso has a higher rate of injection site reactions vs Cerdelga based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Elelyso but not Cerdelga, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cerdelga
Elelyso
At A Glance
Oral
Once or twice daily
Glucosylceramide synthase inhibitor
IV infusion
Every 2 weeks
Enzyme replacement therapy (glucocerebrosidase)
Indications
- Gaucher Disease, Type 1
- Gaucher Disease, Type 1
Dosing
Gaucher Disease, Type 1 EMs and IMs: 84 mg orally twice daily; PMs: 84 mg orally once daily; dose frequency may be reduced to once daily in EMs and IMs taking concomitant CYP2D6 or CYP3A inhibitors depending on hepatic impairment status.
Gaucher Disease, Type 1 (treatment-naive) 60 units/kg IV every other week as a 60- to 120-minute intravenous infusion.
Gaucher Disease, Type 1 (switching from imiglucerase) Initiate at the same units/kg imiglucerase dosage via IV infusion (60- to 120-minute) every other week; adjust dosage based on achievement and maintenance of therapeutic goals.
Contraindications
- EMs taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor
- EMs with moderate or severe hepatic impairment
- EMs with mild hepatic impairment taking a strong or moderate CYP2D6 inhibitor
- IMs taking a strong or moderate CYP2D6 inhibitor concomitantly with a strong or moderate CYP3A inhibitor
- IMs taking a strong CYP3A inhibitor
- IMs with any degree of hepatic impairment
- PMs taking a strong CYP3A inhibitor
- PMs with any degree of hepatic impairment
—
Adverse Reactions
Most common (>=10%) fatigue, headache, nausea, diarrhea, back pain, pain in extremities, upper abdominal pain
Most common (>=5%), treatment-naive adults Headache, arthralgia, fatigue, nausea, dizziness, abdominal pain, pruritus, flushing, vomiting, urticaria
Most common (>=10%), switched from imiglucerase Arthralgia, headache, pain in extremity
Postmarketing Vomiting, diarrhea, fatigue, anaphylaxis, type III immune mediated fixed drug eruption, back pain
Pharmacology
Eliglustat is a specific inhibitor of glucosylceramide synthase (IC50 = 10 ng/mL) that acts as a substrate reduction therapy for Gaucher disease type 1 by reducing the production of glucosylceramide (GL-1), thereby alleviating GL-1 accumulation in the liver, spleen, bone marrow, and other target organs.
Enzyme replacement therapy; taliglucerase alfa is a recombinant analog of human lysosomal glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide, reducing substrate accumulation in macrophages of patients with Gaucher disease.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cerdelga
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Elelyso
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Cerdelga
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (0/8)
Elelyso
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cerdelga
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Elelyso
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Gaucher Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Gaucher Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CerdelgaView full Cerdelga profile
ElelysoView full Elelyso profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.